Scilex Holding announced that one Midwestern and one Southern State voted to add ZTlido as a preferred agent to their Medicaid Preferred Drug Lists, PDL, effective as of January 1, 2024. These changes have the potential to improve access to ZTlido for all eligible patients covered under Medicaid in these two states which will provide additional coverage to approximately 5.0 million lives.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SCLX:
- Scilex Holding Company announces that ZTlido® (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State
- Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee
- Scilex announces addition of ZTlido as preferred agent to Medicaid PDL
- Scilex reports November ZTildo gross sales $14M-$15M
- Scilex announces successful FDA audit of enhanced ZTlido manufacturing facility